fbpx Johnson & Johnson Innovation Names Awardees in the Improving Detection of AL Amyloidosis (IDEA) QuickFire Challenge - News | JLABS

Johnson & Johnson Innovation Names Awardees in the Improving Detection of AL Amyloidosis (IDEA) QuickFire Challenge

December 10, 2021 -
1 month ago
Other news

December 10, 2021 —Johnson & Johnson Innovation, together with Janssen Global Services, announced today the awardees in the Improving Detection of AL Amyloidosis (IDEA) QuickFire Challenge.

  • Boston University School of Medicine, an internationally recognized center for amyloidosis research and treatment with one of the largest biorepositories of amyloidosis patient samples in the world, is developing precision diagnostics seeking to provide early detection and optimal management of AL amyloidosis.

  • CellPrint Biotechnology, LLC is partnering with leading researchers to develop a proprietary technology aiming to discover the unknown relationships between molecular expression in immune cells and the clinical status of patients, hoping to provide new insights about pathophysiology and help identify novel biomarkers and drug targets.

  • City of Hope is an NCCN-designated cancer center with multiple myeloma and amyloidosis treatment and research programs pursuing the exploration of left atrial (LA) strain as a novel marker for early cardiac amyloidosis.

  • Mayo Clinic is on a strategic mission to use the latest advances in science and technology to help improve health outcomes for patients, including harnessing artificial intelligence for early detection of AL amyloidosis.

  • Memorial Sloan Kettering Cancer Center is collaborating with Clinical Directors Network (CDN) to conduct an online CME-accredited program aiming to increase awareness of AL amyloidosis and to inform the prevalence, incidence, and diagnostic pathways for AL amyloidosis patients receiving care in NYC.

  • National and Kapodistrian University of Athens, School of Medicine is a team of physicians, pharmacologists, biologists, medicinal chemists, and radiopharmacists who are developing a 99m Tc-radiolabeled tracer aiming to offer high affinity for amyloid fibrils, efficient biodistribution in tissues predominantly affected by systemic amyloidosis, and binding in immunoglobulin light chain amyloid deposits.

  • Protego Biopharma is developing small molecule pharmacological chaperones and UPR modulators for the treatment of protein misfolding diseases.

  • Tufts Medical Center, through its active plasma cell disease program and translational research laboratory, is leveraging its extensive expertise in plasma cell biology, genomics, and modern techniques of genetic analysis to help improve the lives of AL amyloidosis patients.

  • University Medical Center Utrecht combines a team of clinicians and scientists in a focused translational research program aiming to improve the diagnosis and treatment of patients with AL amyloidosis.

To help advance their science, the awardees will receive grant funding from a pool of $2,150,000, access to the Johnson & Johnson Innovation – JLABS ecosystem, and mentorship from experts of the Johnson & Johnson Family of Companies.*

The QuickFire Challenges are managed by Johnson & Johnson Innovation, with the goal to address today’s greatest healthcare challenges.

* Subject to the execution of the necessary agreements and documentation

Related content